Spero Therapeutics, Inc. (SPRO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US84833T1034
Spero Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 66.80 m USD |
| Operating income | 6.31 m USD |
| EBIT | 6.32 m USD |
| Net income | 8.57 m USD |
| Diluted EPS – continuing operations | 0.15 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
More stocks
- Northeast Indiana Bancorp Inc (NIDB)
- Hwacheon Mac (000850.KS)
- Celemics Inc (331920.KQ)
- BioScience Health Innovations, Inc. (BHIC)
- iNtRON Biotechnology Inc (048530.KQ)
- THiRA-UTECH CO. LTD (322180.KQ)
- Autocount Dotcom Berhad (0276.KL)
- Emperor Energy Ltd (EMP.AX)
- TECO Image Systems Co Ltd (5438.TWO)
- Ecocera Optronics Co., Ltd. (6597.TWO)
- THUNDER MOUNTAIN GOLD INC (THMG)
- Skolon AB (SKOLON.ST)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.